التجارب السريرية طلب موعد في مايو كلينيك المواقع والسفر والإقامةالأبحاث 04/12/2020 بالأسفل التجارب السريرية الحالية.10 دراسات في برنامج زراعة نخاع العظام (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Study of Patients Treated for Chronic Granulomatous Disease Since 1995 Rochester, Minn. Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. The purpose of this study is to determine the long term medical condition and daily functioning of patients with CGD after a transplant and if possible, compare these results to patients who do not undergo a transplant. A Study to Assess Feasibility and Benefit of a Patient-reported Outcomes Quality of Life Tool for Hematology and Medical Oncology Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the feasibility and benefit of a patient-reported outcomes quality of life tool for hematology and medical oncology. A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions Rochester, Minn. The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors. A Study to Evaluate Cancer Distress, Psychological Trauma, and Resiliency in Hospitalized Hematopoietic Stem Cell Transplant Patients Jacksonville, Fla. The purpose of this study is to better understand the distress experience of hospitalized patients undergoing hematopoietic stem cell transplant (HSCT), and to examine the relationship between cancer distress, psychological trauma, and resiliency over time. A Study to Evaluate the Role of Gut Microbiome in Cancer Therapy Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to correlate gut microbiome with specific cancer diagnoses and the clinical response (effectiveness), and adverse effects of cancer therapy (single or multiple) and stem cell transplant. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Rochester, Minn. This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation. Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) Rochester, Minn. The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis. A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM) Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM. Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Rochester, Minn., Jacksonville, Fla. This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma. A Study to Evaluate Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation Rochester, Minn. The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. صُنفت كل من مايو كلينك في مدينة روتشستر بولاية مينيسوتا، ومايو كلينك في فينيكس/سكوتسديل بولاية أريزونا، ومايو كلينك في جاكسونفيل بولاية فلوريدا، ضمن أفضل مستشفيات السرطان على المستوى الوطني حسب بيانات 2021-2022 الصادرة عن U.S. News & World Report. اعرف المزيد عن هذا الشرف الرفيع برنامج زراعة نخاع العظامالصفحة الرئيسية للقسمالأقسامطلب تحديد موعدمُلخّصالاختبارات والإجراءاتحالات تم علاجهاالأطباءالأطباء حسب الموقع والتخصصالخبرات & التصنيفاتالمواقع والسفر والإقامةالتجارب السريريةالأبحاثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار من Mayo Clinicالأهليةالمجلدات والنتائجإحالة المرضىالاتصال بنا الأبحاث: الأمر برمته يتوقف على المرضى الأقسامطلب تحديد موعدمُلخّصالاختبارات والإجراءاتحالات تم علاجهاالأطباءالأطباء حسب الموقع والتخصصالخبرات & التصنيفاتالمواقع والسفر والإقامةالتجارب السريريةالأبحاثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار من Mayo Clinicالأهليةالمجلدات والنتائجإحالة المرضى ORG-20193492 الأقسام والمراكز المراكز والأقسام الطبية برنامج زراعة نخاع العظام